NASDAQ · ANIK
Anika Therapeutics Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ANIK: Nov 06, 2026
Anika Therapeutics Inc. Common Stock is expected to report earnings on 11/06/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $0.02. The reported EPS for the same quarter last year was $-0.17.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $0.02 | $0.02 | $0.02 | 1 |
| Dec 2026 | $0.04 | $0.04 | $0.04 | 1 |
| Mar 2027 | $0.04 | $0.04 | $0.04 | 1 |
| Jun 2027 | $0.17 | $0.17 | $0.17 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks- Zacks · Sep 25, 10:19 AM EDTMerck's Remigromig Meets Main Goal in Diabetic Macular Edema StudyMRK's remigromig meets the primary goal in a DME study, showing non-inferiority to ranibizumab while further safety analyses continue.
- Zacks · Sep 25, 8:40 AM EDTIs Anika Therapeutics (ANIK) Outperforming Other Medical Stocks This Year?Here is how Anika Therapeutics (ANIK) and Concentra Group (CON) have performed compared to their sector so far this year.
- Zacks · Sep 23, 9:38 AM EDTAMGN's Dazodalibep Meets Goal in Systemic Sjogren's Disease StudyAmgen's dazodalibep meets its primary goal in a Phase III study, showing sustained improvement in systemic Sjogren's disease activity through week 48.
- Zacks · Sep 21, 11:57 AM EDTNVS Gets Positive CHMP Opinion for Cosentyx for Another IndicationNVS' Cosentyx wins a positive EU opinion for PMR, backed by late-stage data, potentially expanding its use beyond existing inflammatory conditions.
- Zacks · Sep 18, 10:48 AM EDTPBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer BeginsPuma Biotechnology starts the ALISCA-Lung2 phase II study evaluating alisertib in combination with paclitaxel in patients with advanced small cell lung cancer.
- Zacks · Sep 16, 10:56 AM EDTRCKT Aligns With FDA on Completing Phase II Study in Danon DiseaseRocket Pharmaceuticals aligns with the FDA on key phase II study elements for RP-A501, advancing its Danon disease gene therapy program toward completion.
- Zacks · Sep 15, 11:22 AM EDTImmunocore Hits Enrollment Target in Kimmtrak Label Expansion StudyIMCR achieves target enrollment in the phase III TEBE-AM study investigating Kimmtrak in previously treated patients with advanced melanoma.
- Zacks · Sep 10, 11:42 AM EDTRoche Gets FDA Priority Tag for Enspryng in Rare Autoimmune DisorderRHHBY's sBLA for Enspryng wins FDA priority tag for myelin oligodendrocyte glycoprotein antibody-associated disease. A decision is due on Jan. 10, 2027.
- Zacks · Sep 9, 2:47 PM EDTNovartis' Del-desiran Fails Late-Stage DM1 Study, Shares FallNVS' del-desiran fails the HARBOR study's primary endpoint, adding to recent pipeline setbacks as investors await next steps.
- Zacks · Sep 9, 10:05 AM EDTFDA Accepts & Gives Priority Review to Intellia's BLA for HAE DrugNTLA's BLA for lonvo-z wins FDA priority review for the treatment of HAE. A decision from the agency is expected by March 10, 2027.
- Zacks · Sep 4, 10:48 AM EDTABBV's Etentamig Meets Goals in Phase III Multiple Myeloma StudyAbbVie's etentamig meets key phase III goals in multiple myeloma, improving response rates and progression-free survival versus standard therapies.
- Zacks · Sep 3, 11:23 AM EDTTEVA's TEV '408 Meets Goal in Phase IIa Celiac Disease StudyTeva's TEV '408 meets its phase IIa celiac disease goal, preventing gluten-induced intestinal damage and showing a favorable safety profile.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Anika Therapeutics Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.